TY - JOUR
T1 - Conditional survival of patients treated with first-line chemotherapy for metastatic urothelial cancer
AU - Santoni, Matteo
AU - Crabb, Simon J.
AU - Conti, Alessandro
AU - Rossi, Lorena
AU - Burattini, Luciano
AU - Conteduca, Vincenza
AU - Chau, Caroline
AU - Burgio, Salvatore L.
AU - Muzzonigro, Giovanni
AU - Cascinu, Stefano
AU - De Giorgi, Ugo
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Abstract Background Measures of prognosis for cancer patients are typically evaluated at the time of diagnosis. However, this study assessed the changes in 2-year CS rates after first-line chemotherapy for metastatic UC. Patients and Methods Conditional overall survival and CPFS probability were estimated using the Kaplan-Meier method. Adjusted survival functions were stratified according to age groups (<70 years vs. ≥ 70 years), sex, Eastern Cooperative Oncology Group (ECOG) performance status (PS; ECOG PSA ≤ 2 vs. ECOG PS > 2), pretreatment Hb levels (<12 mg/dL vs. ≥ 12 mg/dL) and pretreatment NLR (<3 vs. ≥ 3). Pairs of CS curves were compared using the Mantel-Haenszel log-rank test. Results Two hundred ninety-eight patients were included in this analysis, 233 were male, and their median age was 69 years. First-line median overall survival and progression-free survival were 10.7 months (95% confidence interval [CI], 9.6-12.6) and 6.0 months (95% CI, 5.5-7.1), respectively. CPFS and COS showed an increasing trend in the population considered (b = 0.35; P
AB - Abstract Background Measures of prognosis for cancer patients are typically evaluated at the time of diagnosis. However, this study assessed the changes in 2-year CS rates after first-line chemotherapy for metastatic UC. Patients and Methods Conditional overall survival and CPFS probability were estimated using the Kaplan-Meier method. Adjusted survival functions were stratified according to age groups (<70 years vs. ≥ 70 years), sex, Eastern Cooperative Oncology Group (ECOG) performance status (PS; ECOG PSA ≤ 2 vs. ECOG PS > 2), pretreatment Hb levels (<12 mg/dL vs. ≥ 12 mg/dL) and pretreatment NLR (<3 vs. ≥ 3). Pairs of CS curves were compared using the Mantel-Haenszel log-rank test. Results Two hundred ninety-eight patients were included in this analysis, 233 were male, and their median age was 69 years. First-line median overall survival and progression-free survival were 10.7 months (95% confidence interval [CI], 9.6-12.6) and 6.0 months (95% CI, 5.5-7.1), respectively. CPFS and COS showed an increasing trend in the population considered (b = 0.35; P
KW - Advanced urothelial cancer
KW - Conditional Survival
KW - Overall survival
KW - Prognosis
KW - Progression-free survival
UR - http://www.scopus.com/inward/record.url?scp=84929080716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929080716&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2014.10.003
DO - 10.1016/j.clgc.2014.10.003
M3 - Article
C2 - 25465492
AN - SCOPUS:84929080716
VL - 13
SP - 244
EP - 249
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
SN - 1558-7673
IS - 3
M1 - 333
ER -